Scan to Download ios&Android APP

Trade CNS Pharmaceuticals, Inc. - CNSP CFD

0.25
0%
0.03
Low: 0.24
High: 0.24
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.24
Open* 0.24
Day's Range* 0.24 - 0.24
1-Year Change* 14.29%
Volume N/A
Average Vol. (3m) 12.9565
52 wk Range N/A
Market Cap 10.0562
P/E Ratio N/A
Shares Outstanding 40032500
Revenue N/A
EPS -0.4611
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 11, 2022 0.24 0.00 0.00% 0.24 0.24 0.24
Aug 10, 2022 0.24 0.01 4.35% 0.23 0.24 0.23
Aug 9, 2022 0.24 0.00 0.00% 0.24 0.24 0.22
Aug 8, 2022 0.23 0.01 4.55% 0.22 0.24 0.22
Aug 5, 2022 0.21 -0.01 -4.55% 0.22 0.22 0.21
Aug 4, 2022 0.21 0.00 0.00% 0.21 0.21 0.21
Aug 3, 2022 0.20 0.00 0.00% 0.20 0.20 0.20
Aug 2, 2022 0.20 0.00 0.00% 0.20 0.20 0.20
Aug 1, 2022 0.20 -0.01 -4.76% 0.21 0.21 0.20
Jul 29, 2022 0.20 -0.01 -4.76% 0.21 0.21 0.20
Jul 28, 2022 0.20 0.00 0.00% 0.20 0.20 0.20
Jul 27, 2022 0.20 0.00 0.00% 0.20 0.21 0.20
Jul 26, 2022 0.20 -0.01 -4.76% 0.21 0.21 0.20
Jul 25, 2022 0.21 0.00 0.00% 0.21 0.22 0.21
Jul 21, 2022 0.22 0.01 4.76% 0.21 0.22 0.21
Jul 20, 2022 0.22 -0.01 -4.35% 0.23 0.23 0.22
Jul 19, 2022 0.21 -0.02 -8.70% 0.23 0.23 0.21
Jul 18, 2022 0.23 -0.02 -8.00% 0.25 0.25 0.22
Jul 15, 2022 0.23 -0.01 -4.17% 0.24 0.25 0.23
Jul 14, 2022 0.24 -0.01 -4.00% 0.25 0.26 0.24

CNS Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total revenue 0 0 0 0 0
Total Operating Expense 0.21511 7.16863 3.83298 9.45461 14.0273
Selling/General/Admin. Expenses, Total 0.18247 0.86052 1.97864 4.39287 4.68084
Research & Development 0.03264 0.02127 1.85433 5.06173 9.34645
Unusual Expense (Income) 0 6.28684 0
Operating Income -0.21511 -7.16863 -3.83298 -9.45461 -14.0273
Interest Income (Expense), Net Non-Operating -0.00426 -0.0467 -0.04423 -0.00326 -0.00929
Other, Net 0 -0.17657 0
Net Income Before Taxes -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Net Income After Taxes -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Net Income Before Extra. Items -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Total Extraordinary Items 0
Net Income -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Income Available to Common Excl. Extra. Items -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Income Available to Common Incl. Extra. Items -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Diluted Net Income -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Diluted Weighted Average Shares 15.712 15.712 13.6479 16.6184 26.3533
Diluted EPS Excluding Extraordinary Items -0.01396 -0.47046 -0.28409 -0.56912 -0.53263
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.01396 -0.07033 -0.28409 -0.56912 -0.53263
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 3.60966 3.81132 3.8134 2.79292 2.78177
Selling/General/Admin. Expenses, Total 1.40278 1.14634 1.23539 0.89633 1.26041
Research & Development 2.20687 2.66498 2.57802 1.89658 1.52136
Operating Income -3.60966 -3.81132 -3.8134 -2.79292 -2.78177
Interest Income (Expense), Net Non-Operating -0.00375 -0.00235 -0.00095 -0.00224 -0.00257
Net Income Before Taxes -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Net Income After Taxes -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Net Income Before Extra. Items -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Net Income -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Income Available to Common Excl. Extra. Items -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Income Available to Common Incl. Extra. Items -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Diluted Net Income -3.6134 -3.81367 -3.81435 -2.79515 -2.78434
Diluted Weighted Average Shares 24.6644 25.4327 27.4438 27.8385 38.8083
Diluted EPS Excluding Extraordinary Items -0.1465 -0.14995 -0.13899 -0.10041 -0.07175
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.1465 -0.14995 -0.13899 -0.10041 -0.07175
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total Current Assets 0.16219 0.58813 7.89391 15.4958 7.47745
Cash and Short Term Investments 0.11054 0.28274 7.24129 14.0395 5.00452
Cash & Equivalents 0.11054 0.28274 7.24129 14.0395 5.00452
Prepaid Expenses 0.05165 0.033 0.65262 1.45635 2.47293
Other Current Assets, Total 0 0.2724 0
Total Assets 0.16219 0.68333 7.91208 15.8534 8.75739
Other Long Term Assets, Total 0 0.0952 0 0.33414 1.26383
Total Current Liabilities 0.22073 1.23263 0.311 1.90543 2.13557
Accounts Payable 0.0425 0.12807 0.24367 0.94633 1.52282
Payable/Accrued 0.015 0.00079 0.04583 0
Accrued Expenses 0.0414 0.0236 0.0215 0.5198 0.22495
Notes Payable/Short Term Debt 0.12183 0.31692 0 0.43929 0.38779
Other Current Liabilities, Total 0 0.76325 0
Total Liabilities 0.22073 1.23263 0.311 1.90543 2.13557
Total Long Term Debt 0 0 0 0 0
Total Equity -0.05853 -0.5493 7.60108 13.948 6.62182
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.01027 0.0127 0.01645 0.02386 0.02793
Additional Paid-In Capital 0.15056 7.04927 19.0731 34.8705 41.5768
Retained Earnings (Accumulated Deficit) -0.21936 -7.61126 -11.4885 -20.9463 -34.9829
Total Liabilities & Shareholders’ Equity 0.16219 0.68333 7.91208 15.8534 8.75739
Total Common Shares Outstanding 15.712 15.712 16.4502 23.8561 27.9272
Property/Plant/Equipment, Total - Net 0.01817 0.02343 0.01611
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 12.7864 13.8835 11.1558 7.47745 14.7332
Cash and Short Term Investments 11.0752 6.88557 8.32622 5.00452 12.4405
Cash & Equivalents 11.0752 6.88557 8.32622 5.00452 12.4405
Total Receivables, Net 0.13265 3.70177
Accounts Receivable - Trade, Net 0.13265 0.13265
Prepaid Expenses 1.57852 3.29615 2.82961 2.47293 2.29267
Total Assets 13.1446 14.2385 11.5075 8.75739 15.8719
Property/Plant/Equipment, Total - Net 0.02411 0.0209 0.01753 0.01611 0.01273
Other Long Term Assets, Total 0.33414 0.33414 0.33414 1.26383 1.12596
Total Current Liabilities 1.90176 1.83075 2.40743 2.13557 1.0693
Accounts Payable 1.05768 0.89249 1.46157 1.52282 0.48972
Accrued Expenses 0.53494 0.76068 0.90122 0.22495 0.30701
Notes Payable/Short Term Debt 0.30913 0.17758 0.04463 0.38779 0.27257
Total Liabilities 1.90176 1.83075 2.40743 2.13557 1.0693
Total Long Term Debt 0 0 0 0 0
Total Equity 11.2429 12.4078 9.10007 6.62182 14.8026
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.02535 0.02738 0.02746 0.02793 0.04003
Additional Paid-In Capital 35.7772 40.7538 41.2604 41.5768 52.5298
Retained Earnings (Accumulated Deficit) -24.5597 -28.3734 -32.1878 -34.9829 -37.7673
Total Liabilities & Shareholders’ Equity 13.1446 14.2385 11.5075 8.75739 15.8719
Total Common Shares Outstanding 25.3528 27.3795 27.4607 27.9272 40.0325
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Net income/Starting Line -0.21936 -7.3919 -3.87721 -9.45787 -14.0366
Cash From Operating Activities -0.1122 -0.71639 -3.55347 -7.31802 -13.5383
Non-Cash Items 0.05992 6.59174 0.7474 1.29498 1.72384
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0 0.00399 0.00171 0.00977
Changes in Working Capital 0.04725 0.08378 -0.42562 0.83378 -1.23864
Cash From Financing Activities 0.22274 1.16098 10.2598 14.1342 4.50908
Financing Cash Flow Items 0 0.47048 0 -0.045 0
Issuance (Retirement) of Stock, Net 0.10092 0.3905 10.2948 14.2222 4.98657
Issuance (Retirement) of Debt, Net 0.12183 0.3 -0.035 -0.04308 -0.47749
Net Change in Cash 0.11054 0.44459 6.68616 6.79821 -9.03498
Cash From Operating Activities 0.00196 0.0111 0.01307
Cash From Investing Activities -0.02012 -0.01795 -0.00575
Capital Expenditures -0.02012 -0.01795 -0.00575
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -3.6134 -7.42708 -11.2414 -14.0366 -2.78434
Cash From Operating Activities -3.30805 -8.30599 -10.3015 -13.5383 -3.0772
Cash From Operating Activities 0.003 0.00621 0.00958 0.01307 0.00338
Non-Cash Items 0.43068 0.90029 1.40694 1.72384 0.33669
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0.00421 0.00721 0.00721 0.00977 0.00288
Changes in Working Capital -0.12833 -1.78541 -0.4766 -1.23864 -0.63292
Cash From Investing Activities -0.00367 -0.00367 -0.00367 -0.00575 0
Capital Expenditures -0.00367 -0.00367 -0.00367 -0.00575 0
Cash From Financing Activities 0.34743 1.15574 4.59191 4.50908 10.5132
Issuance (Retirement) of Stock, Net 0.47759 1.41745 4.98657 4.98657 10.6284
Issuance (Retirement) of Debt, Net -0.13016 -0.26171 -0.39466 -0.47749 -0.11522
Net Change in Cash -2.96429 -7.15392 -5.71327 -9.03498 7.43598
Financing Cash Flow Items 0 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

CNS Pharmaceuticals, Inc. Company profile

About CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.

Industry: Biotechnology & Medical Research (NEC)

2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US

Income statement

People Also Watch

US Crude Oil Spot

91.34 Price
-2.150% 1D Chg, %
Long position overnight fee 0.0139%
Short position overnight fee -0.0310%
Overnight fee time 21:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading